Excision repair cross-complementation group 1 codon 118 polymorphism, micro ribonucleic acid and protein expression, clinical outcome of the advanced gastric cancer response to first-line FOLFOX-4 in Qinghai-Tibetan plateau population

Journal of Cancer Research and Therapeutics

Volumn 9, Issue 3, 2013, Pages 410-415

  Qi, Yu Juan ^a   Cui, Sen ^a   Yang, Ying Zhong ^a   Han, Jing Qi ^a   Cai, Bao Jia ^a   Sheng, Cun Fang ^a   Ma, Yan ^a   Wuren, Tana ^a   Ge, Ri Li ^a  

^a QINGHAI UNIVERSITY   (China)

Author keywords

Advanced gastric cancer; excision repair cross complementation group 1 micro ribonucleic acid and protein expression; excision repair cross complementation group 1 polymorphism; FOLFOX 4; Qinghai Tibetan plateau

Indexed keywords

EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; FOLINIC ACID; MESSENGER RNA; MICRORNA; OXALIPLATIN; PLATINUM;

ADULT; ADVANCED CANCER; AFRICA; ALTITUDE; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CAUCASIAN; CHEMOTHERAPY; CHINA; CODON; CONTINUOUS INFUSION; CONTROLLED STUDY; ETHNIC DIFFERENCE; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHINA; CODON; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOTYPE; HUMANS; LEUCOVORIN; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; POLYMORPHISM, SINGLE NUCLEOTIDE; SEQUENCE ANALYSIS, DNA; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84885571885     PISSN: 09731482     EISSN: 19984138     Source Type: Journal    
DOI: 10.4103/0973-1482.119319     Document Type: Article

References (33)

1. Yang L. Incidence and mortality of gastric cancer in China. World J Gastroenterol 2006;12: 17-20.
2. Louvet C, André T, Tigaud JM, Gamelin E, Douillard JY, Brunet R, et al. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 2002;20: 4543-8.
3. Al-Batran SE, Atmaca A, Hegewisch-Becker S, Jaeger D, Hahnfeld S, Rummel MJ, et al. Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol 2004;22: 658-63.
4. Chao Y, Yeh KH, Chang CJ, Chen LT, Chao TY, Wu MF, et al. Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer. Br J Cancer 2004;91: 453-8.
5. Wei J, Zou Z, Qian X, Ding Y, Xie L, Sanchez JJ, et al. ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen. Br J Cancer 2008;98: 1398-402.
6. Chang PM, Tzeng CH, Chen PM, Lin JK, Lin TC, Chen WS, et al. ERCC1 codon 118 C→T polymorphism associated with ERCC1 expression and outcome of FOLFOX-4 treatment in Asian patients with metastatic colorectal carcinoma. Cancer Sci 2009;100: 278-83.
7. Kalikaki A, Kanaki M, Vassalou H, Souglakos J, Voutsina A, Georgoulias V, et al. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clin Lung Cancer 2009;10: 118-23.
8. Dabholkar M, Bradshaw L, Parker RJ, Gill I, Bostick-Bruton F, Muggia FM, et al. Cisplatin-DNA damage and repair in peripheral blood leukocytes in vivo and in vitro. Environ Health Perspect 1992;98: 53-9.
9. Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 1998;24: 331-44.
10. De Silva IU, McHugh PJ, Clingen PH, Hartley JA. Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells. Mol Cell Biol 2000;20: 7980-90.
11. Raymond E, Faivre S, Woynarowski JM, Chaney SG. Oxaliplatin: Mechanism of action and antineoplastic activity. Semin Oncol 1998;25: 4-12.
12. Altaha R, Liang X, Yu JJ, Reed E. Excision repair cross complementinggroup 1: Gene expression and platinum resistance. Int J Mol Med 2004;14: 959-70.
13. Kwon HC, Roh MS, Oh SY, Kim SH, Kim MC, Kim JS, et al. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol 2007;18: 504-9.
14. Smith S, Su D, Rigault de la Longrais IA, Schwartz P, Puopolo M, Rutherford TJ, et al. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy. J Clin Oncol 2007;25: 5172-9.
15. Handra-Luca A, Hernandez J, Mountzios G, Taranchon E, Lacau-St- Guily J, Soria JC, et al. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma. Clin Cancer Res 2007;13: 3855-9.
16. Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatinbased adjuvant chemotherapy. N Engl J Med 2006;355: 983-91.
17. Ferry KV, Hamilton TC, Johnson SW. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: Role of ERCC1-XPF. Biochem Pharmacol 2000;60: 1305-13.
18. Bramson J, Panasci LC. Effect of ERCC-1 overexpression on sensitivity of Chinese hamster ovary cells to DNA damaging agents. Cancer Res 1993;53: 3237-40.
19. Park DJ, Stoehlmacher J, Zhang W, Tsaowei D, Groshen S, Lenz HJ. ERCCl polymorphism is associated with differential ERCCl gene expression. In: American Association for Cancer Research. San Francisco, CA: ASCO Proceedings; 2002.
20. Yu JJ, Mu C, Lee KB, Okamoto A, Reed EL, Bostick-Bruton F, et al. A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues. Mutat Res 1997;382: 13-20.
21. Stoehlmacher J, Park DJ, Zhang W, Yang D, Groshen S, Zahedy S, et al. A multivariate analysis of genomic polymorphisms: Prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 2004;91: 344-54.
22. Isla D, Sarries C, Rosell R, Alonso G, Domine M, Taron M, et al. Single nucleotide polymorphisms and outcome in docetaxelcisplatin- treated advanced non-small-cell lung cancer. Ann Oncol 2004;15: 1194-203.
23. Park DJ, Zhang W, Stoehlmacher J, Tsao-Wei D, Groshen S, Gil J, et al. ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy. Clin Adv Hematol Oncol 2003;1: 162-6.
24. Viguier J, Boige V, Miquel C, Pocard M, Giraudeau B, Sabourin JC, et al. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res 2005;11: 6212-7.
25. Ruzzo A, Graziano F, Loupakis F, Rulli E, Canestrari E, Santini D, et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 2007;25: 1247-54.
26. Kamikozuru H, Kuramochi H, Hayashi K, Nakajima G, Yamamoto M. ERCC1 codon 118 polymorphism is a useful prognostic marker in patients with pancreatic cancer treated with platinum-based chemotherapy. Int J Oncol 2008;32: 1091-6.
27. Martinez-Balibrea E, Abad A, Aranda E, Sastre J, Manzano JL, Díaz-Rubio E, et al. Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as firstline chemotherapy in advanced colorectal cancer. Eur J Cancer 2008;44: 1229-37.
28. Steffensen KD, Waldstrom M, Jakobsen A. DNA-Repair ERCC1 gene polymorphisms in epithelial ovarian cancer and relation to platinum resistance and survival. J Cancer Ther 2011;2: 140-7.
29. Uchida K, Danenberg PV, Danenberg KD, Grem JL. Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine. BMC Cancer 2008;8: 386.
30. Booton R, Ward T, Ashcroft L, Morris J, Heighway J, Thatcher N. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer. J Thorac Oncol 2007;2: 902-6.
31. Takenaka T, Yano T, Kiyohara C, Miura N, Kouso H, Ohba T, et al. Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients. Lung Cancer 2010;67: 101-7.
32. Shao YY, Kuo KT, Hu FC, Lu YS, Huang CS, Liau JY, et al. Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin. Jpn J Clin Oncol 2010;40: 286-93.
33. Vodicka P, Kumar R, Stetina R, Sanyal S, Soucek P, Haufroid V, et al. Genetic polymorphisms in DNA repair genes and possible links with DNA repair rates, chromosomal aberrations and single-strand breaks in DNA. Carcinogenesis 2004;25: 757-63.